UB Paderborn / Katalog / Suche / in CDI

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

Annals of oncology, 2019-12, Vol.30 (Suppl_10), p.x27-x42

2019

Volltextzugriff (PDF)

Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)

Annals of oncology, 2018-10, Vol.29, p.viii79-viii79

2018

Volltextzugriff (PDF)

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis

ESMO open, 2021-04, Vol.6 (2), p.100066-100066, Article 100066

2021

Volltextzugriff (PDF)

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

ESMO open, 2021-04, Vol.6 (2), p.100091-100091, Article 100091

2021

Volltextzugriff (PDF)

A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e13-e14

2024

Volltextzugriff (PDF)

KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e14

2024

Volltextzugriff (PDF)

247PShould anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

44P The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis

Annals of oncology, 2020-12, Vol.31, p.S1433-S1434

2020

Volltextzugriff (PDF)

101P Accuracy of detecting PIK3CA mutations on circulating tumour (ct) DNA as compared to tumour tissue (TT) in breast cancer (BC) patients (pts): Results from a systematic review and meta-analysis

Annals of oncology, 2020-09, Vol.31, p.S281-S282

2020

Volltextzugriff (PDF)

170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial

Annals of oncology, 2020-09, Vol.31, p.S310-S310

2020

Volltextzugriff (PDF)

1849P Safety and effectiveness of palliative chemotherapy (CTX) for patients (pts) with malignant bowel obstruction (MBO)

Annals of oncology, 2020-09, Vol.31, p.S1059-S1060

2020

Volltextzugriff (PDF)

Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”

Annals of oncology, 2020-10, Vol.31 (10), p.1423

2020

Volltextzugriff (PDF)

Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”: Annals of Oncology 2020; volume 31, supplement 2; s71 (abstr. 153P)

Annals of oncology, 2020-10, Vol.31 (10), p.1423-1423

2020

Volltextzugriff (PDF)

221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO

Annals of oncology, 2020-09, Vol.31, p.S329-S330

2020

Volltextzugriff (PDF)

188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis

Annals of oncology, 2020-05, Vol.31, p.S84-S85

2020

Volltextzugriff (PDF)

153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials

Annals of oncology, 2020-05, Vol.31, p.S71-S71

2020

Volltextzugriff (PDF)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

Annals of oncology, 2019-12, Vol.30 Suppl 10, p.x27

2019

Volltextzugriff (PDF)

ALBUMIN NANOPARTICLES: AN INTERESTING ALTERNATIVE FOR THE CONTROLLED RELEASE OF DRUGS

Tchê química, 2018-08, Vol.15 (30), p.705-716

2018

Volltextzugriff (PDF)

1181P Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches

Annals of oncology, 2022-09, Vol.33, p.S1088

2022

Volltextzugriff (PDF)

Ionic liquids as solubility/permeation enhancers for topical formulations: Skin permeation and cytotoxicity characterization

Toxicology letters, 2015-10, Vol.238 (2), p.S293-S293

2015

Volltextzugriff (PDF)

3052 Prophylactic cranial irradiation for extensive stage small cell lung cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S613-S613

2015

Volltextzugriff (PDF)

700 Pulmonary nodules and metastases in non-pulmonary solid tumor bearing patients

European journal of cancer (1990), 2015-09, Vol.51, p.S127-S127

2015

Volltextzugriff (PDF)

2D triangular Ising model with bond phonons: an entropic simulation study

The European physical journal. B, Condensed matter physics, 2024-06, Vol.97 (6), Article 73

2024

Volltextzugriff (PDF)

Photoinhibition in chilling stressed wheat and maize

Photosynthetica, 2001-06, Vol.39 (2), p.161-166

2001

Volltextzugriff (PDF)

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9158-TPS9158

2023

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation

KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

247PShould anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)

44P The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis

101P Accuracy of detecting PIK3CA mutations on circulating tumour (ct) DNA as compared to tumour tissue (TT) in breast cancer (BC) patients (pts): Results from a systematic review and meta-analysis

170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial

1849P Safety and effectiveness of palliative chemotherapy (CTX) for patients (pts) with malignant bowel obstruction (MBO)

Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”

221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO

188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis

153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

ALBUMIN NANOPARTICLES: AN INTERESTING ALTERNATIVE FOR THE CONTROLLED RELEASE OF DRUGS

1181P Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches

Ionic liquids as solubility/permeation enhancers for topical formulations: Skin permeation and cytotoxicity characterization

3052 Prophylactic cranial irradiation for extensive stage small cell lung cancer

700 Pulmonary nodules and metastases in non-pulmonary solid tumor bearing patients

2D triangular Ising model with bond phonons: an entropic simulation study

Photoinhibition in chilling stressed wheat and maize

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

Suchergebnisse filtern